This is a working overview of Cardarine, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-01. Anything still debated is marked as such rather than presented as settled.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Klara Valko is a scientist, consultant, academic and author. She is the director of Bio-Mimetic Chromatography as well as an honorary professor at University College London School of Pharmacy. Valko is most known for her work on early drug discovery and lead optimization. Among her authored works are her publications in academic journals, as well as books such as Chromatographic Determination of Molecular Interactions and Physicochemical and Biomimetic Properties in Drug Discovery: Chromatographic Techniques for Lead Optimization.
On 2 February, she met in Miraflores Palace with Delcy and Jorge Rodríguez to establish "the work agenda between the Bolivarian Republic of Venezuela and the United States." After the meeting, the US embassy shared on social media that Dogu met with the Venezuelan administration to "reiterate the three phases that US Secretary of State Marco Rubio had outlined for Venezuela: stabilization, economic recovery and reconciliation, and transition." Felix Plasencia was named as diplomatic representative of Venezuela to the United States. United States Energy Secretary Chris Wright arrived to Caracas on 11 February to make an assessment on Venezuela's oil industry. He met with Delcy Rodríguez in the presidential palace. Days before, Wright said he was expecting to "visit some of the nation's oil fields to see firsthand how President Trump's historic US-Venezuela Energy Deal is unleashing peace and prosperity." According to the Venezuelan information minister, they discussed a bilateral energy agenda. The last US Energy Secretary that visited Venezuela before that was Bill Richardson in 2001 under US president Bill Clinton. Dogu and Plasencia received a US shipment of six metric tons of medicine and medical supplies that arrived in Venezuela on 13 February. Dogu indicated it was "the first of many donations" that will arrive "in the coming days". Plasencia said that it was a "message of cooperation among two sovereign countries." When asked by reporters on 13 February, Trump said that he was "going to make a visit to Venezuela" but did not provide more details.
There were other witnesses for the defense who did not show up. Several scientists who had been listed as potential witnesses for the state, backed out because of what Clark termed "peer pressure." Another state witness, Dr. Dean Kenyon, a biophysicist at San Francisco State University, mysteriously disappeared on the eve of his day in court. He had flown into Little Rock on a Sunday evening, but when one of Clark's assistants went to take his deposition he could not find him. Kenyon had checked out of the hotel and flown back home. Bird had encouraged Kenyon not to testify, although Kenyon taught evolution theory for 16 years until three years ago when he became a creationist. Bird, who is general counsel to Institute for Creation Research, said he attempted to get other defense witnesses not to testify after he perceived the trial as botched by Clark.
Sources: en.wikipedia.org
== Nitrogen-15 == Nitrogen-15 is a rare stable isotope of nitrogen, comprising about 0.38%. Nitrogen-15 presents one of the lowest thermal neutron capture cross sections of all isotopes. Nitrogen-15 is frequently used in NMR (Nitrogen-15 NMR spectroscopy). Unlike the more abundant nitrogen-14, which has an integer nuclear spin and thus a quadrupole moment, 15N has a fractional nuclear spin of one-half, which offers advantages for NMR such as narrower line width. As most nitrogen NMR studies look at a single nitrogen atom in an organic molecule, isotopic labeling is feasible. Nitrogen-15 tracing is a technique used to study the nitrogen cycle.
Tecemotide (INN; emepepimut-S (USAN); formerly known as BLP25 or EMD 531444) is a synthetic lipopeptide that is used as antigen in an investigational therapeutic cancer vaccine (formerly known as Stimuvax, L-BLP25, BLP25 liposomal vaccine, or BLP25 liposome vaccine). The investigational therapeutic cancer vaccine is designed to induce a cellular immune response to cancer cells that express MUC1, a glycoprotein antigen that is widely over-expressed on common cancers such as lung cancer, breast cancer, prostate cancer, and colorectal cancer. The cellular immune response may lead to a rejection of tumor tissue expressing the MUC1 antigen.
Pharmacists are healthcare professionals with specialized education and training who perform various roles to ensure optimal health outcomes for their patients through the quality use of medicines. Pharmacists may also be small business proprietors, owning the pharmacy in which they practice. Since pharmacists know about the mode of action of a particular drug, and its metabolism and physiological effects on the human body in great detail, they play an important role in optimization of drug treatment for an individual. Pharmacists are represented internationally by the International Pharmaceutical Federation (FIP), an NGO linked with World Health Organization (WHO). They are represented at the national level by professional organisations such as the Royal Pharmaceutical Society in the UK, Pharmaceutical Society of Australia (PSA), Canadian Pharmacists Association (CPhA), Indian Pharmacist Association (IPA), Pakistan Pharmacists Association (PPA), American Pharmacists Association (APhA), and the Malaysian Pharmaceutical Society (MPS). In some cases, the representative body is also the registering body, which is responsible for the regulation and ethics of the profession. In the United States, specializations in pharmacy practice recognized by the Board of Pharmacy Specialties include: cardiovascular, infectious disease, oncology, pharmacotherapy, nuclear, nutrition, and psychiatry. The Commission for Certification in Geriatric Pharmacy certifies pharmacists in geriatric pharmacy practice.
=== Shape === Circulating inactivated platelets are biconvex discoid (lens-shaped) structures, 2–3 μm in greatest diameter. Activated platelets have cell membrane projections covering their surface. In a first approximation, the shape can be considered similar to oblate spheroids, with a semiaxis ratio of 2 to 8. This approximation can be used to model the hydrodynamic and optical properties of a population, as well as to restore the geometric parameters of individual measured platelets by flow cytometry. More accurate biophysical models of platelet surface morphology that model its shape from first principles make it possible to obtain a more realistic platelet geometry in a calm and activated state.
Sources: en.wikipedia.org
Within hours of his January 2025 inauguration, Trump signed an executive order withdrawing the country from the 2015 Paris Agreement, joining only Iran, Libya and Yemen as the only countries not party to the agreement. The same day, Trump issued Executive Order 14154, "Unleashing American Energy", which included pausing funding for the Inflation Reduction Act, introducing uncertainty as to the energy transition. His administration soon renewed a practice from his first term: removing mentions of climate change across numerous federal government websites that had been reinstated during Joe Biden's intervening term. In February 2025, the administration terminated the Environmental and Climate Justice Block Grant Program. In June 2026, district judge Richard Gergel ruled that the terminations were unlawful and in July 2026 a federal judge ordered the program's remaining $2.8 billion in funds be distributed. In April, Trump dismissed the scientists and experts who compile the National Climate Assessments (NCAs) that are required by Congress, the next assessment having been planned for 2028. The globalchange.gov website—established in 1990 to host legislatively mandated reports such as the NCAs—was taken down altogether at the end of June. In May 2025, NOAA said that its National Centers for Environmental Information would no longer update its Billion-Dollar Weather and Climate Disasters database beyond 2024, and that its information—going as far back as 1980—would be archived.
The company set up a ghostwriting programme called CASPPER, initially to produce articles about Paxil but which was extended to cover Avandia. As part of the settlement GSK signed a five-year corporate integrity agreement with the Department of Health and Human Services, which obliged the company to make major changes in the way it did business, including changing its compensation programmes for its sales force and executives, and to implement and maintain transparency in its research practices and publication policies. It announced in 2013, that it would no longer pay doctors to promote its drugs or attend medical conferences, and that its sales staff would no longer have prescription targets.
=== Ion mobility spectrometry === Explosive detection using ion mobility spectrometry (IMS) is based on velocities of ions in a uniform electric field. There are some variant to IMS such as Ion trap mobility spectrometry (ITMS) or Non-linear dependence on ion mobility (NLDM) which are based on IMS principle. The sensitivity of devices using this technology is limited to pg levels. The technology also requires the ionization of sample explosives which is accomplished by a radioactive source such as nickel-63 or americium-241. This technology is found in most commercially available explosive detectors such as the GE VaporTracer, Smith Sabre 4000 and Russian built MO-2M and MO-8. The presence of radioactive materials in these equipments cause regulatory hassles and requires special permissions at customs ports. These detectors cannot be field serviced and may pose radiation hazard to the operator if the casing of the detector cracks due to mishandling. Bi-yearly checks are mandatory on such equipment in most countries by regulating agencies to ensure that there are no radiation leaks. Disposal of these equipments is also controlled owing to the high half-life of the radioactive material used. Electrospray ionization, mobility analysis (DMA) and tandem mass spectrometry (MS/MS) is used by SEDET (Sociedad Europea de Detección) for the “Air Cargo Explosive Screener (ACES)”, targeted to aviation cargo containers currently under development in Spain.
== Medical uses == In the EU, migalastat is indicated for the long-term treatment of people aged 16 years of age and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. In the US, migalastat is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data. An "amenable" mutation is one that leads to misfolding of the enzyme, but otherwise would not significantly impair its function. Based on an in vitro test, Amicus Therapeutics has published a list of 269 amenable and nearly 600 non-amenable mutations. About 35 to 50% of people with Fabry have an amenable mutation.
Endocrine glands derive from all three germ layers. The natural decrease in function of the female's ovaries during late middle age results in menopause. The efficiency of all endocrine glands seems to decrease gradually as ageing occurs. This leads to a generalized increase in the incidence of diabetes mellitus and a lower metabolic rate.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.